低分子肝素钙治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者的剂量强度与疗效研究  

Study on dose intensity and efficacy of low molecular weight heparin calcium in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD)

作　　者：余竹青 Yu Zhuqing(Hunan Rehabilitation Hospital,Changsha,Hunan 410000,China)

机构地区：[1]湖南省康复医院,湖南长沙410000

出　　处：《首都食品与医药》2025年第5期67-69,共3页Capital Food Medicine

摘　　要：目的 评估不同剂量强度低分子肝素钙对慢性阻塞性肺疾病急性加重期(AECOPD)患者的疗效.方法 本次入组的90例AECOPD患者均选自本院在2023年1月-2024年1月期间收治的患者,以不同剂量的低分子肝素钙分组,三组均为5000AXaU/C次,大剂量组3次/日、中剂量组2次/日,小剂量组1次/日,每组各30例,对比疗效.结果 经治疗后,三组的肺功能指标均升高,且中、大剂量组均比小剂量组高(P<0.05);中、大剂量组均比小剂量组PT和APTT指标长,且中、大剂量组均比小剂量组FIB指标低(P<0.05),中、大剂量组无明显差异(P>0.05);中、大剂量组均比小剂量组氧代谢指标高(P<0.05),而中、大剂量组无明显差异(P>0.05);小、中剂量组的不良反应发生率均较大剂量组低(P<0.05),但小、中剂量组差异小(P>0.05).结论 中、大剂量的低分子肝素钙治疗可提高AECOPD患者的肺功能与氧代谢指标,改善凝血功能,较小剂量低分子肝素钙效果更优,但大剂量较小、中剂量低分子肝素钙治疗的不良反应发生率高.Objective To evaluate the effect of different dose intensity low molecular weight heparin calcium on patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods 90 patients with AECOPD were selected from our hospital from January 2023 to January 2024,and were divided into different doses of low molecular weight heparin calcium(LMCC),the three groups were 5000AXaU/C times,the large-dose group was 3 times/day,the medium-dose group was 2 times/day,and the small-dose group was 1 time/day,with 30 cases each.Results After treatment,the pulmonary function indexes of the three groups were increased,and the medium and large dose groups were higher than the small dose group(P<0.05).The PT and APTT indexes in medium and large dose groups were longer than those in small dose group,and the FIB indexes in medium and large dose groups were lower than those in small dose group(P<0.05).There was no difference between medium and large dose groups(P>0.05).The oxygen metabolism indexes of medium and large dose groups were higher than those of small dose group(P<0.05).There was no difference between medium and large dose groups(P>0.05).The probability of adverse reactions in small and medium dose groups was lower in large dose group(P<0.05).There was little difference between small and medium dose groups(P>0.05).Conclusion Medium and large doses of low molecular weight heparin calcium therapy can improve the pulmonary function and oxygen metabolism indexes of AECOPD patients,and improve coagulation function.Small doses of low molecular weight heparin calcium therapy have better effects,but large doses of low and medium doses of low molecular weight heparin calcium therapy has a high probability of adverse reactions.

关 键 词：低分子肝素钙 慢性阻塞性肺疾病急性加重期 肺功能 氧代谢 不良反应 

分 类 号：R563[医药卫生—呼吸系统]